Placenta extract shows promise for liver disease in early trial
NCT ID NCT05532124
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 2 trial tested LAENNEC, a substance made from human placenta, in 49 adults with chronic liver disease. The study aimed to check if the treatment is safe and whether it can improve liver function, measured by a drop in ALT levels. Participants received either LAENNEC or a placebo through an IV, and researchers compared side effects and ALT changes between the groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LAENNEC (human placenta hydrolysate)
What this could lead to
If successful, this could point toward a new treatment option to improve liver health in people with chronic liver disease.
What could go wrong
This is a small, early-phase trial (Phase 2) with only 49 participants. The results may not apply to everyone, and the treatment may not prove effective in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hanyang University Hospital.
Seoul, South Korea
-
Keimyung university dongsan medical center
Daegu, South Korea
-
Korea university guro hospital
Seoul, South Korea
-
Severance hospital
Seoul, South Korea
-
Soonchunhyang university hospital
Seoul, South Korea
-
Wonju severance christian hospital
Wŏnju, South Korea
-
Yeungnam university
Daegu, South Korea